Zev M Nakamura1,2, Allison M Deal3, Donald L Rosenstein4,3,5, Laura J Quillen4, Stephanie A Chien4, William A Wood3,5, Thomas C Shea3,5, Eliza M Park4,3,5. 1. Department of Psychiatry, University of North Carolina at Chapel Hill, 101 Manning Drive, Campus Box #7160, Chapel Hill, NC, 27599, USA. zev_nakamura@med.unc.edu. 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. zev_nakamura@med.unc.edu. 3. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Department of Psychiatry, University of North Carolina at Chapel Hill, 101 Manning Drive, Campus Box #7160, Chapel Hill, NC, 27599, USA. 5. Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
PURPOSE: Cognitive impairment is common and consequential in patients with cancer who undergo allogeneic hematopoietic stem cell transplantation (HSCT). However, there is no standard of care for evaluating cognition in patients prior to or after receiving HSCT, and it is not known which patients are at highest risk for cognitive impairment. The objectives of this study were to describe cognitive function in patients prior to allogeneic HSCT and identify demographic, disease-related, and psychosocial factors associated with cognitive function. METHODS: Prior to HSCT, participants completed the Montreal Cognitive Assessment (MoCA). We assessed bivariable associations between continuous MoCA scores and demographic, disease-related, and psychosocial variables using linear regression. Variables significant at the p < 0.2 level were adjusted for age, sex, and years of education in multiple linear regression analyses. RESULTS: Over 50% of participants demonstrated evidence of cognitive impairment (MoCA < 26) prior to transplantation. When adjusted for demographic variables, two characteristics were significantly associated with worse cognitive function: the hematopoietic cell transplantation-comorbidity index score (p = 0.01) and history of alcohol or substance abuse (p = 0.02). Pre-HSCT cancer and cancer treatment-specific variables were not associated with cognitive function. CONCLUSION: Cognitive impairment is common in patients scheduled to receive HSCT. Pre-transplantation evaluation of medical comorbidities and history of substance abuse may be important in identifying patients at risk for cognitive impairment. Further research characterizing the trajectory and impact of cognitive impairment on patient symptom burden and function may help improve outcomes.
PURPOSE: Cognitive impairment is common and consequential in patients with cancer who undergo allogeneic hematopoietic stem cell transplantation (HSCT). However, there is no standard of care for evaluating cognition in patients prior to or after receiving HSCT, and it is not known which patients are at highest risk for cognitive impairment. The objectives of this study were to describe cognitive function in patients prior to allogeneic HSCT and identify demographic, disease-related, and psychosocial factors associated with cognitive function. METHODS: Prior to HSCT, participants completed the Montreal Cognitive Assessment (MoCA). We assessed bivariable associations between continuous MoCA scores and demographic, disease-related, and psychosocial variables using linear regression. Variables significant at the p < 0.2 level were adjusted for age, sex, and years of education in multiple linear regression analyses. RESULTS: Over 50% of participants demonstrated evidence of cognitive impairment (MoCA < 26) prior to transplantation. When adjusted for demographic variables, two characteristics were significantly associated with worse cognitive function: the hematopoietic cell transplantation-comorbidity index score (p = 0.01) and history of alcohol or substance abuse (p = 0.02). Pre-HSCT cancer and cancer treatment-specific variables were not associated with cognitive function. CONCLUSION: Cognitive impairment is common in patients scheduled to receive HSCT. Pre-transplantation evaluation of medical comorbidities and history of substance abuse may be important in identifying patients at risk for cognitive impairment. Further research characterizing the trajectory and impact of cognitive impairment on patient symptom burden and function may help improve outcomes.
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer Journal: Blood Date: 2005-06-30 Impact factor: 22.113
Authors: Richard J Lin; Armin Shahrokni; Parastoo B Dahi; Ann A Jakubowski; Sean M Devlin; Molly A Maloy; Kevin S Robinson; Miguel-Angel Perales; Gunjan L Shah; Beatriz Korc-Grodzicki; Sergio A Giralt Journal: Bone Marrow Transplant Date: 2018-03-09 Impact factor: 5.483
Authors: Lachlan J McDowell; Jolie Ringash; Wei Xu; Biu Chan; Lin Lu; John Waldron; Kathy Rock; Nathaniel So; Shao Hui Huang; Meredith Giuliani; Andrew Hope; Brian O'Sullivan; Scott V Bratman; John Cho; John Kim; Raymond Jang; Andrew Bayley; Lori J Bernstein Journal: Radiother Oncol Date: 2018-09-29 Impact factor: 6.280
Authors: Melissa A Friedman; Mercedes Fernandez; Jeffrey S Wefel; Katherine A Myszka; Richard E Champlin; Christina A Meyers Journal: Arch Clin Neuropsychol Date: 2009-09-18 Impact factor: 2.813
Authors: Marleen J J Pullens; Jolanda De Vries; Laurence J C Van Warmerdam; Marieke A Van De Wal; Jan A Roukema Journal: Psychooncology Date: 2012-10-30 Impact factor: 3.894
Authors: David Buchbinder; Debra Lynch Kelly; Rafael F Duarte; Jeffery J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne B Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary D E Flowers; Bipin Savani; Bronwen E Shaw Journal: Bone Marrow Transplant Date: 2018-01-17 Impact factor: 5.483